Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

NCT01808950 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped safety issues

Conditions

Nodular Basal Cell Carcinoma

Interventions

DRUG: 0.06% Resiquimod Gel - A
DRUG: 0.06% Resiquimod Gel - B
DRUG: 0.06% Resiquimod Gel - C

Sponsor

Spirig Pharma Ltd.